Kalytera's CBD prevents graft-vs-host disease  Kalytera Therapeutics Inc. (TSX-V:KLY; OTCQB:KALTF) announced plans to start a Phase III registrational trial of cannabidiol after low and medium doses reduced the incidence of Grade 2-4 acute graft-versus-host disease...

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies. The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics...

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline. Abbisko Therapeutics Co. Ltd. (Shanghai, China)...

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first...